LncRNA-PVT1 enhances glucose metabolism of pediatric low-grade glioma cells through sponging miR-187-3p

Beibei Li, Zijian Feng, Yanyan ZhengPolish 2024 · DOI

Abstract

Pediatric low-grade glioma (PLGG) is a heterogeneous group of primary central nervous system malignancies and the most frequent brain tumors in children. While diagnosis and treatment have improved, the molecular mechanisms underlying PLGG oncogenesis remain elusive. This study investigates the role of the long non-coding RNA (lncRNA) PVT1 in PLGG progression. We found that PVT1 is significantly upregulated in PLGG tissues and correlates with poor patient survival. Mechanistically, PVT1 acts as a molecular "sponge" for miR-187-3p, which is downregulated in tumor tissues. Blocking PVT1 effectively suppressed glucose metabolism in PLGG-derived cells, a process mediated through the regulation of miR-187-3p. These findings suggest that the PVT1/miR-187-3p axis is a critical regulator of the Warburg effect in PLGG.

Introduction: PLGG and the Warburg Effect

Pediatric low-grade glioma (PLGG) is the most frequent central nervous system malignancy in children. Although many cases have a favorable prognosis, tumors located in surgically inaccessible areas pose a significant threat, leading to high morbidity. A hallmark of cancer is metabolic reprogramming—specifically the Warburg effect, where cancer cells preferentially use glycolysis for energy even when oxygen is plentiful. This provides the biomass needed for rapid tumor growth. While the role of lncRNAs in cancer is well-documented, their specific influence on the metabolic machinery of PLGG has remained largely unexplored. This research investigates whether the lncRNA PVT1 drives this metabolic shift.

Clinical Significance of PVT1

Analysis of 35 pairs of PLGG tumor tissues and adjacent normal brain tissues revealed a significant upregulation of PVT1 in malignant samples ($p < 0.001$). Furthermore, high expression of PVT1 was strongly correlated with decreased survival probability in patients. Public database analysis (KM Plotter) showed that patients with high PVT1 expression faced a survival probability drop to nearly 0% by 6,000 days, whereas the low-expression group maintained significantly higher survival rates.

PVT1 expression in PLGG tissues and its impact on patient survival.

The PVT1/miR-187-3p Regulatory Axis

The study identified a competitive endogenous RNA (ceRNA) mechanism where PVT1 functions as a molecular "sponge." Bioinformatics and dual-luciferase reporter assays confirmed that PVT1 contains a binding site for miR-187-3p, effectively sequestering it and preventing its tumor-suppressive functions. While PVT1 is upregulated in PLGG, miR-187-3p is significantly downregulated, and their expression levels are negatively correlated in clinical samples. RNA pull-down assays using biotin-labeled probes confirmed a high-affinity physical interaction between these two molecules.

Metabolic Reprogramming in PLGG Cells

To determine the functional impact of this axis, researchers performed silencing experiments in PLGG-derived cell lines (Res186 and BT66). Silencing PVT1 using siRNA led to a significant reduction in glucose uptake (measured by 2-DG6P assays) and lactate production, effectively slowing the glycolytic rate by approximately 40-50%.

Silencing PVT1 significantly reduces glucose uptake in BT66 PLGG cells.

Rescue experiments validated this functional link: the metabolic inhibition caused by silencing PVT1 was successfully reversed by introducing miR-187-3p inhibitors. This confirms that PVT1’s effect on glucose metabolism is specifically mediated through its interaction with this microRNA.

Conclusion and Future Directions

This study identifies PVT1 as a potential metabolic target for treating pediatric gliomas. By sponging miR-187-3p, PVT1 accelerates the glucose metabolism necessary for tumor progression. However, the authors acknowledge limitations, including the need for in vivo xenograft mouse experiments to verify these findings in a living system. Additionally, the specific downstream messenger RNAs (mRNAs) targeted by miR-187-3p to regulate the enzymatic machinery of glycolysis remain to be identified in future research.

Summary updated

Abstract

Pediatric low-grade glioma (PLGG) is a heterogeneous group of primary central nervous system malignancies which represent the most frequent brain tumors in children. Although diagnosis and treatment of PLGG have been improved recently, the molecular mechanisms underlying the oncogenesis and progression of PLGG remain elusive. Studies have revealed critical roles of long non-coding RNAs (lncRNAs) in brain tumor progressions. Here, we aimed to investigate the clinical roles and molecular mechanisms of lncRNA PVT1 in PLGG. Expression of PVT1 was significantly upregulated in PLGG tissues compared with normal brain tissues. Blocking PVT1 effectively suppressed the glucose metabolism of PLGG-derived cells. MicroRNA-187-3p was detected to be remarkedly downregulated in PLGG tissues. Moreover, miR-187-3p is negatively correlated with PVT1 in PLGG tissues. We identified PVT1 sponged miR-187-3p to block its expression in PLGG cells. This association was further verified by RNA pull-down and luciferase assay. Subsequently, rescue experiments validated that inhibition of miR-187-3p in PVT1-silenced PLGG cells successfully overcame the low-PVT1-induced miR-187-3p upregulation and glucose metabolism. In summary, this study reports critical roles and molecular mechanisms of the lncRNA PVT1-accelarated glucose metabolism of PLGG cells.
BibTeX
@inproceedings{li2024lncrna,
  author = {Beibei Li and Zijian Feng and Yanyan Zheng},
  title = {{LncRNA-PVT1 enhances glucose metabolism of pediatric low-grade glioma cells through sponging miR-187-3p}},
  booktitle = {Polish},
  year = {2024},
  doi = {10.5114/pjp.2024.146455},
}
Figure